Gertz BJ, 187
Getsy J, 1168
Gillen LP, 831, 1091
Gilsanz F, 397
Gleave M, 983
Gobburu JVS, 1307
Goldammer M, 1101
Goldberg MR, 912
Goldstein JA, 84
Gomez-Mancilla B, 342
Gonzalez HM, 1211
Gordi T, 1161
Gottesdiener K, 573
Gottesdiener KM, 268, 912, 1136
Graf JA, 414
Granda BW, 414
Grant M, 29
Green MD, 692
Greenberg H, 573
Greenberg HE, 831, 983, 1091
Greenblatt DJ, 414
Grimm S, 443
Grossman M, 228
Guell A, 1235
Guillevic Y, 901
Gwilt PR, 1003
Haanæs HR, 305, 849
Hackett J, 342
Hak EB, 7
Hale V, 624
Hansen KT, 649
Harder AT, 807
Harmatz JS, 414
Harper D, 943, 1168
Hasegawa S, 1268
Hatorp V, 649
Hauck WW, 831, 1091
Hausheer FH, 1008
Hawkey CJ, 573
Hayase Y, 859
Hayes KC, 379
Hayney MS, 1377
He W, 1203
Hebert MF, 38
Henderson GN, 386
Henry RR, 1228
Herman BD, 423
Hermann R, 243, 1257
Hernández L, 291
Hesney M, 912
Hewitt RG, 171
Hicks RW, 760
Hinderliter AL, 84
Hochhaus G, 29, 365
Hoffman A, 711
Holm S, 470
Honaker MR, 555
Hong C, 1161
Hopkins NJ, 1161
Hoppel CL, 881
Horowitz A, 359
Houin G, 1235
Hoyer PF, 141
Hoyo-Vadillo C, 1211
Hsieh JTC, 379
Hsu C, 154
Huang S-M, 342
Hubert M, 359
Hunt TL, 268, 1341
Hurwitz A, 996
Hutson AD, 386, 683
Ide S, 342
Iga T, 122
Iinuma M, 859
Imbimbo BP, 901
Ingalls ST, 881
Ingrosso A, 43
Ingwersen SH, 66
Ito S, 743
Iwai S, 1268
Jabbour JT, 721
James LP, 7, 840
Jauregui L, 1082
Jensen BK, 365, 1341
Jia X, 180
Jin N, 974
Johne A, 1101
Johnson CS, 894
Johnson FK, 74, 148
Johnson PW, 990
Jones CR, 406
Jones DP, 7
Jørgensen M, 23
Judson R, 816
Jusko WJ, 1168, 1216
Kakafika A, 825
Kanda H, 1392
Kaneko S, 122
Kanitra L, 428
Kao J, 443
Kao R, 735, 1361
Karim A, 943
Kato T, 859
Katz MA, 379
Kearns G, 7, 148, 840, 1196
Keefe DL, 327
Kemper EM, 604
Kent JD, 504
Khouri MS, 943
Killinger J, 342
Kim D, 1228
Kim YH, 610
Kimler BF, 996
Kinchelow T, 1382
King SP, 443
Kirch W, 228
Kitler ME, 477
Klausner EA, 711
Klipping C, 243
Kolis S, 1382
Kondo T, 122
Koren G, 743
Kotb M, 555
Kovarik JM, 141
Kraft WK, 983
Krause SL, 1203
Kraynak RA, 840
Krishna S, 386
Krüger H, 1101
Krum H, 1203
Kubota T, 122
Kuge T, 284
Kumar G, 443
Kumar N, 193
Kuti JL, 1116
Kuypers DRJ, 866
Lacouture P, 296
Lai A, 59
Lai JC-K, 1149
Lam YWF, 1274
Lambrecht L, 359
Lane JR, 610
Langholff WK, 141
Larson PJ, 1082, 1136
Lasseter KC, 268, 1136
Lates CD, 1216
Lathers CM, 491
Lavit M, 1235
Lavy E, 711
Lee CR, 84
Lee JS, 163
Lee Y, 912
Leese PT, 504
Lehmann DF, 1316
Leighton J, 342
Lesko LJ, 342
Le-Traon AP, 1235
Li S, 555
Li X, 881
Liang E, 1361
Lin CC, 591
Lin SX, 1216
Liu M-J, 610
Lo M-W, 591
Locher M, 243
Loew C, 943
Lopez-Candales A, 586
Lozano K F, 1211
Lu Z, 1370
Lynn M, 735
Ma T, 296
Machoy P, 524
Madden T, 1008
Maes B, 866
Mager DE, 1216
Mahmood I, 692
Mai I, 1101
Majka S, 881
Major P, 154
Majumdar AK, 912
Malhotra S, 193
Manouilov KK, 1003
Mansfield E, 342
Maples HD, 7
Marino M, 1361
Marion AS, 141
Mariotti F, 901
Martin LL, 529
Martin NE, 529
Matthews CZ, 268, 1136
Mayo M, 624
Mayo MS, 996
Mazenko R, 1082
Mazina KE, 268
Mazzu A, 260
McBride BF, 1071
McCrea JB, 268
McGuire D, 624
McKinney RE, 133
McLeod J, 443
McLeod JF, 163, 359
McMahon L, 141
McMeekin J, 760
McNabb J, 1003
Medicis JJ, 1316
Meibohm B, 555
Méndez P, 397
Mertzanis P, 414
Meyer R, 342
Michiels N, 912
Mihara K, 122
Milionis HJ, 825
Miller AK, 252
Miller M, 1274
Miller WH Jr, 154
Miwa G, 443
Mohustsy MA, 643
Moore R, 428
Morrison D, 59
Morse GD, 171
Mottern RK, 721
Mousa SA, 727
Mucci M, 43
Mudaliar S, 1228
Muindi JR, 894
Mukhopadhyay S, 187
Muller D, 1377
Müller M, 29, 1244
Mulligan TE, 428
Murakami M, 859
Murphy MG, 912
Murphy WR, 943

Musser BJ, 268
Nagaraja NV, 243, 386, 683
Nara K, 1268
Narang A, 968
Nave R, 365
Newman RA, 1008
Ni L, 443
Nickens DJ, 43
Nicolau DP, 1116
Nieforth K, 1382
Nielsen KK, 23, 1244
Nightingale CH, 1116
Noe A, 141
Novalbos J, 397
Obach SR, 443
O'Connell D, 624
Ogawa K, 1268
Oguchi K, 1268
Okerholm R, 59
Orellana M, 1299
Orlowski LH, 912
Osborne S, 359
Otani K, 1392
Ouellet D, 128
Owusu-Ofori A, 386
Pabst G, 1244
Páez X, 291
Palumbo P, 133
Pandhi P, 193
Papakostas J, 825
Parasrampuria DA, 406
Parier J-L, 180
Passalacqua W, 1299
Patel IH, 1382
Pechstein B, 243
Pendrak RF, 754
Pendyala L, 1324
Peng Y, 894
Pequignot E, 831
Peregrina L AA, 1211
Perez R, 1324
Persky AM, 29
Pesco-Koplowitz L, 180
Petty KJ, 912, 1136
Pieper JA, 84
Piga A, 565
Piotrovsky V, 514
Pirenne J, 866
Pitari GM, 983
Planche T, 386
Pluda JM, 1124
Polasek ED, 974
Popescu G, 15
Porras AG, 187, 268, 1082, 1136
Posvar EL, 277
Potter PJ, 379
Prasad P, 163
Preiss R, 1257
Prescilla RP, 1283
Prisant LM, 1203
Pudlo A, 524
Rajagopalan P, 260, 698
Ramabadran K, 840
Ramjit D, 591
Randinitis EJ, 277
Ravens U, 228
Ravera C, 154
Recker DP, 504
Reed E, 1124
Reinhardt RR, 1228
Rice P, 74
Ritter MA, 591
Rivera G, 1299
Robatel C, 1329
Roberts JP, 38
Roberts S, 443
Rock D, 1108
Rodrigo R, 1299
Rodríguez CA, 43
Roe A, 443
Rohatagi S, 365, 1341
Roman D, 128
Roman K, 943
Romero T EM, 1211
Rondelli I, 901
Roniker B, 1203
Roots I, 1101
Rordorf R, 141
Rose JR, 735
Rose MJ, 268, 1136
Rosito G, 643
Rossignol D, 735
Rouan M-C, 565
Rudek MA, 1124
Ruhl CE, 996
Ruus P, 1257
Ruxrungtham K, 1382
Ryan JL, 1108
Ryan SG, 342
Séchaud R, 565
Sack M, 252
Sainati SM, 974
Saivin S, 1235
Salerno RA, 342
Sandhu RS, 1283
Santell JP, 760
Santos MA, 397
Sarapa N, 974
Satoh S, 859
Schaller MD, 1329
Schlagheck T, 296
Schmith V, 342
Schneck D, 943
Schraeder PL, 491
Schran H, 154
Schwartz JI, 187, 268, 1082
Schwertschlag US, 1108
Seaman J, 154
Séchaud R, 565
Sedman AJ, 277
Seferiadis K, 825
Sehgal G, 1370
Shader RI, 414
Shah A, 443
Shah B, 1341
Shahinfar S, 591
Sharma JN, 1187
Sharma PK, 193, 968
Shaw P, 342
Shelton MJ, 171
Shibata T, 284
Shimoda N, 859
Shindler C, 228
Shroads AL, 386
Simonelli TM, 1283
Sista S, 1149
Sistare F, 342
Skerjanec A, 154
Skoglund LA, 305, 849
Skrumsager BK, 66, 1244
Slatter JG, 1161
Smith HT, 163
Smith JA, 1008
Smith PF, 1324
Smith SG, 637
Snavely D, 591
Snikeris F, 443
Soares-da-Silva P, 1350
Song P, 555
Sonnichsen DS, 943
Spear BB, 342
Spector SA, 133
Spiro TP, 881
Springer MA, 1196
Stacpoole PW, 386, 683
Stalker DJ, 943
Stepensky D, 711
Stern R, 118
Störmer E, 1101
Stockis A, 1370
Stowe CD, 7
Stratemans R, 1370
Streetman DS, 637
Sullivan JT, 443
Sundaresan P, 260
Suzuki A, 1392
Suzuki T, 859
Swan SK, 359
Swindells SS, 1003
Tada H, 859
Takarada Y, 122
Tamer HR, 637
Tan LH, 1161
Tankanow R, 637
Tardif S, 529
Tarral A, 901
Tateishi T, 122
Teichert J, 1257
Thompson-Culkin K, 252
Thomsen MS, 23, 470, 649
Topp EM, 996
Trump DL, 894
Tserng K-Y, 881
Tweedie D, 443
Udaka Y, 1268
Uresin Y, 237
van den Anker JN, 840
van Giersbergen PLM, 15
Van Osselaer N, 514
Van Peer A, 514
Vanapalli SR, 1108
VanBuren S, 983
VanDenBerg CM, 604
Vanrenterghem Y, 866
Vega JM, 443
Venitz J, 1124
Veronese ML, 831, 1091
Victory JM, 92, 539
Viswanathan-Aiyer K-J, 187
Vogt B, 7
von Moltke LL, 414
Wacher VJ, 38
Wagner J, 573
Wagner JA, 943, 983
Waldman S, 573
Waldman SA, 831, 983, 1091
Waldmeier F, 154
Wallace AW, 92, 539
Walsh J, 443
Walson PD, 128
Walter YH, 163
Warholm C, 1158
Warren S, 1108
Watson M, 342
Wehling M, 912
Wells TG, 7
Welton JL, 637
Wermeling D, 624
West K, 586
Weston IE, 148
Whitaker A-M, 990
White CM, 1071
White D, 1082
Wight N, 573
Wilczek H, 1158
Wilding I, 529
Willett MS, 284
Williams PJ, 610
Willson JKV, 881
Wilson JT, 7, 1196
Wilson JW, 894
Wise SD, 943

Wojcicki J, 524
Wolf DL, 43
Wolfe DL, 379
Wong P, 573
Wong YN, 735, 1361
Woodland C, 743
Woolf EJ, 268, 1136
Worobec A, 342
Wray H, 529
Wrighton SA, 443
Xia C, 260
Xie C, 180
Yasui-Furukori N, 122, 1392
Yates CR, 555
Zagaria N, 477
Zagrobelny J, 591
Zammit K, 586
Zech K, 365
Zegarac EA, 52
Zhang J, 1341
Zhang W, 555
Zhang X, 1382
Zhao Q, 180
Zhi J, 428
Zhou H, 211, 359
Zimmerman JJ, 1168

Subject Index, Volume 43 (2003)

Acetaminophen

influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study, 1235

ketoprofen 75 mg qid versus acetaminophen 1000 mg qid for three days on swelling, pain, and other postoperative events after third-molar surgery, 305

naproxen 500 mg bid versus acetaminophen 1000 mg qid: effect on swelling and other acute postoperative events after bilateral third molar surgery, 849

Adverse events

effect of inhaled steroids on bone mineral density: a meta-analysis, 193

isoniazid-induced anaphylaxis, 545

AERx insulin diabetes management system

young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison, 1228

Almotriptan

interaction between ketoconazole and almotriptan in healthy volunteers, 423

Alzheimer's disease

galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations, 514

Amiodarone

effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers, 428

Analgesia

ketoprofen 75 mg qid versus acetaminophen 1000 mg qid for three days on swelling, pain, and other postoperative events after third-molar surgery, 305

naproxen 500 mg bid versus acetaminophen 1000 mg qid: effect on swelling and other acute postoperative events after bilateral third molar surgery, 849

pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients, 624

randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain, 296

Anaphylaxis

isoniazid-induced anaphylaxis, 545

Arachidonic acid concentration

relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation, 983

Atenolol

effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans, 524

Atorvastatin

comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia, 825

β-Thalassemia

safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia, 565

BIA 3-202

pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-*O*-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects, 1350

Bone healing

mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review, 807

Bone mineral density

effect of inhaled steroids on bone mineral density: a meta-analysis, 193

Bosentan

influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist, 15

Calcium

lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in health volunteers, 92

lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers, 539

Cancer

factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies, 1124

a limited sampling method for the estimation of serum calcitroil area under the curve in cancer patients, 894

pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function, 154

Cardiac repolarization

valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization, 974

Cardiovascular abnormalities

does the kinin system mediate in cardiovascular abnormalities? an overview, 1187

Case studies

renal transplantation in a case of acute intermittent porphyria, 1158

Cerebrospinal fluid

pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients, 1003

Cetrorelix

pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women, 243

CHF 3381

safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects, 901

Ciclesonide

population pharmacokinetics and pharmacodynamics of ciclesonide, 365

Cidofovir

pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis, 43

Ciprofloxacin

population pharmacokinetics of ciprofloxacin in pediatric patients, 698

Clinical studies

can renin status predict the antihypertensive efficacy of eplerenone add-on therapy, 1203

comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia, 825

factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies, 1124

Clinical study

safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study, 735

Clinical trials

COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial, 504

Coagulation

are coagulation times biomarkers? Data from a phase I study of the oral thrombin inhibitor LB-30057 (CI-1028), 118

COL-3

factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies, 1124

Corticosteroids

dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics, 1216

Creatine

single- and multiple-dose pharmacokinetics of oral creatine, 29

Cyclooxygenase-2

single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man, 268

Cyclosporine

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients, 1101

pharmacokinetics of cyclosporine pre- and post-liver transplantation, 38

CYP1A2

an evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe, 1082

CYP2C19

CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans, 1211

CYP2D6

effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia, 122

CYP3A4

CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans, 1211

effect of influenza immunization on CYP3A4 activity in vivo, 1377

effect of mibefradil on CYP3A4 in vivo, 1091

exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice, 831

influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide, 649

CYP3A5

effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients, 555

Cysteine

pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion, 1324

Cytochrome P450 2C19

polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of *Helicobacter pylori* infection associated with duodenal ulcer, 1316

Cytomegalovirus retinitis

pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis, 43

Dental surgery

ketoprofen 75 mg qid versus acetaminophen 1000 mg qid for three days on swelling, pain, and other postoperative events after third-molar surgery, 305

naproxen 500 mg bid versus acetaminophen 1000 mg qid: effect on swelling and other acute postoperative events after bilateral third molar surgery, 849

Diabetes

pharmacokinetics of nateglinide in renally impaired diabetic patients, 163

Diabetes type 2

ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes, 1244

young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison, 1228

Dichloroacetate

efficacy of dichloroacetate as a lactate-lowering drug, 683

population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children, 386

Diethylcarbamazine citrate (DEC)

ensuring supplies of quality diethylcarbamazine citrate (DEC), 477

Digoxin

bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example, 743

interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*), 637

lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects, 912

Donepezil

pharmacokinetic and safety assessment of concurrent administration of risperidone and donepezil, 180

Drug absorption

pharmacokinetic strategies in deciphering atypical drug absorption profiles, 211

Drug development

are coagulation times biomarkers? Data from a phase I study of the oral thrombin inhibitor LB-30057 (CI-1028), 118

biomarkers in drug discovery and development: from target identification through drug marketing, 329

conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective, 443

ensuring supplies of quality diethylcarbamazine citrate (DEC), 477

evaluation of the cohort size in phase I dose escalation trials based on laboratory data, 470

pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-Dru-Safe workshop, 342

pharmacokinetic strategies in deciphering atypical drug absorption profiles, 211

a review and assessment of potential sources of ethnic differences in drug responsiveness, 943

selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance, 692

Drug interactions

bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example, 743

conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective, 443

drug interaction potential of soy extract and panax ginseng, 643

effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects, 187

effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers, 428

evaluation of in vitro drug interaction with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development, 1008

influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide, 649

influence of goldenseal root on the pharmacokinetics of indinavir, 1283

interaction between ketoconazole and almotriptan in healthy volunteers, 423

interaction study between fluvoxamine and quazepam, 1392

lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in health volunteers, 92

lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers, 539

lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects, 912

pharmacokinetic and safety assessment of concurrent administration of risperidone and donepezil, 180

pharmacokinetics interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and four hours apart in healthy volunteers, 1168

pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E, 1161

pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone, 414

Drug metabolism

an evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe, 1082

CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans, 1211

effect of influenza immunization on CYP3A4 activity in vivo, 1377

effect of mibefradil on CYP3A4 in vivo, 1091

effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-

hydroxyrisperidone in Japanese patients with schizophrenia, 122
exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice, 831
lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide, 1382
tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans, 84

Drug responsiveness
a review and assessment of potential sources of ethnic differences in drug responsiveness, 943

Drug trials
role of the research-subject locator (RSL) in the performance of a pediatric drug trial, 1196

E5564
pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function, 1361
safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study, 735

Education
a model of pharmacology education: the experience of Istanbul medical faculty, 237

Elderly
COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial, 504
gastric function in the elderly: effects on absorption of ketoconazole, 996
young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison, 1228

Enfuvirtide
lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide, 1382

Enoxaparin
correlation of antifactor Xa concentrations with renal function in patients on enoxaparin, 586

Eplerenone
can renin status predict the antihypertensive efficacy of eplerenone add-on therapy, 1203

Erectile dysfunction
effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, 260

Estradiol
effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy, 52

Ethnic differences
a review and assessment of potential sources of ethnic differences in drug responsiveness, 943

Etoricoxib
characterization of etoricoxib, a novel, selective COX-2 inhibitor, 573
pharmacokinetics of etoricoxib in patients with hepatic impairment, 1136
single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man, 268

Famotidine
disposition in children and adolescents with chronic renal insufficiency, 7

Fampridine
pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury, 379

Fenofibrate
comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia, 825

Fluoxetine
effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers, 428
pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

Flurbiprofen
tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans, 84

Fluvoxamine
interaction study between fluvoxamine and quazepam, 1392
pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

Food
clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics, 141
effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy, 52
effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031, 1341
exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice, 831
influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects, 59
lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal, 990
lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers, 539
tyramine pharmacokinetics and reduced bioavailability with food, 604

Food and Drug Administration (FDA)
pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-Dru-Safe workshop, 342

Furosemide
furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers, 711

γ agonist
ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes, 1244

Galantamine
galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations, 514

Gastric functions
gastric function in the elderly: effects on absorption of ketoconazole, 996

Gatifloxacin
lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in health volunteers, 92

Gender
influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects, 59

Ginseng
drug interaction potential of soy extract and panax ginseng, 643

Goldenseal root
influence of goldenseal root on the pharmacokinetics of indinavir, 1283

Hand vein responses
reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin $F_{2\alpha}$ using the dorsal hand vein compliance method, 228

Hawthorn (*Crataegus oxyacantha*)
interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*), 637

HCl
pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration, 1149

Hemodiafiltration
pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients, 1329

Heparin
pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects, 727

Hepatic function
pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function, 1361

Hepatic impairment
pharmacokinetics of etoricoxib in patients with hepatic impairment, 1136

Herbal medicine

drug interaction potential of soy extract and panax ginseng, 643

interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*), 637

multiple-dose escalation, safety, and tolerability study of wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medication in healthy subjects, 284

topical hemostatic effect of a common ornamental plant, the geraniaceae *Pelargonium zonale*, 291

influence of goldenseal root on the pharmacokinetics of indinavir, 1283

HIV

delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity, 171

pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients, 1003

pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis, 43

population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children, 133

HMR1031

effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031, 1341

Homocysteine

homocysteine and essential hypertension, 1299

Hormone replacement therapy

effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy, 52

Hydroxyurea

pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients, 1003

Hydrochlorothiazide

pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment, 591

Hyperlipidemia

comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia, 825

Hypertension

homocysteine and essential hypertension, 1299

Ibuprofen

pharmacokinetics of oral ibuprofen in premature infants, 968

ICL670

safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia, 565

Indinavir

influence of goldenseal root on the pharmacokinetics of indinavir, 1283

Infection

polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of *Helicobacter pylori* infection associated with duodenal ulcer, 1316

Influenza

effect of influenza immunization on CYP3A4 activity in vivo, 1377

Istanbul medical faculty

a model of pharmacology education: the experience of Istanbul medical faculty, 237

Karenitecin

evaluation of in vitro drug interaction with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development, 1008

Ketoconazole

gastric function in the elderly: effects on absorption of ketoconazole, 996

interaction between ketoconazole and almotriptan in healthy volunteers, 423

pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

Ketoprofen

ketoprofen 75 mg qid versus acetaminophen 1000 mg qid for three days on swelling, pain, and other postoperative events after third-molar surgery, 305

Kidney

bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example, 743

Kidney transplant

chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection, 859

Kinin system

does the kinin system mediate in cardiovascular abnormalities? an overview, 1187

Lactic acidosis

population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children, 386

Lamotrigine

clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios, 491

Levetiracetam

levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets, 1370

Levofloxacin

lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal, 990

lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers, 539

Levosimedan

levosimedan: implications for clinicians, 1071

Lidocaine

safety and tolerability of the lidocaine patch 5 a targeted peripheral analgesic: a review of the literature, 111

Linezolid

pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E, 1161

Liver impairment

influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist, 15

Liver transplantation

pharmacokinetics of cyclosporine pre-and post-liver transplantation, 38

Losartan

pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment, 591

tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans, 84

Luteninzing hormone

pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women, 243

M100240

pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers, 529

Malaria

population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children, 386

MDR1

effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients, 555

***MDR1* haplotypes**

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients, 1101

Medication errors

an analysis comparing PHICO's closed claims data and PHICO's event reporting trending system (PERTS), 754

experience of the United States Pharmacopeia (UPS) MEDMARX reporting system, 760

minimizing medication errors: practical pointers for prescribers, 751

reducing medication errors and increasing patient safety: case studies in clinical pharmacology, 768

Meropenem

pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients, 1329

use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem, 1116

Methods

reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin $F_{2\alpha}$ using the dorsal hand vein compliance method, 228

Mibefradil

effect of mibefradil on CYP3A4 in vivo, 1091

Microemulsion

pharmacokinetics interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and four hours apart in healthy volunteers, 1168

Midazolam

pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

Mifepristone

bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example, 743

Mitogen

single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study, 406

Modeling

considerations in analyzing single-trough concentrations using mixed-effects modeling, 1307

Moxidectin

antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans, 1108

Naproxen

naproxen 500 mg bid versus acetaminophen 1000 mg qid: effect on swelling and other acute postoperative events after bilateral third molar surgery, 849

Nateglinide

pharmacokinetics of nateglinide in renally impaired diabetic patients, 163

Nazatidine

bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule, 148

Nefazodone

pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

Nizatidine

pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects, 74

Nonsteroidal

mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review, 807

Norethindrone

effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl etradiol tablets intended for continuous hormone replacement therapy, 52

O^6-benzylguanine

pharmacokinetics of 0^6-benzylguanine (NSC637037) and its matabolite, 8-oxo-O^6-benzylguanine, 881

Omeprazole

CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans, 1211

omeprazole disposition in children following single-dose administration, 840

Orlistat

effects of orlistat, a Lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers, 428

Oxycodone

randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain, 296

Pain management

see analgesia

Pediatrics

clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics, 141

famotidine disposition in children and adolescents with chronic renal insufficiency, 7

omeprazole disposition in children following single-dose administration, 840

pharmacokinetics of oral ibuprofen in premature infants, 968

pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment, 128

pharmacokinetics of sumatriptan nasal spray in adolescents, 721

population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children, 386

population pharmacokinetics of ciprofloxacin in pediatric patients, 698

population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children, 133

role of the research-subject locator (RSL) in the performance of a pediatric drug trial, 1196

Pharmaceutical Research and Manufactures of America (PhRMA)

conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective, 443

Pharmacogenetics

effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients, 555

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients, 1101

polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of *Helicobacter pylori* infection associated with duodenal ulcer, 1316

using multiple drug exposure levels to optimize power in pharmacogenetic trials, 816

Pharmacokinetics and pharmacodynamics

antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans, 1108

bioequivalence of nizatidine (axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule, 148

characterization of etoricoxib, a novel, selective COX-2 inhibitor, 573

chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection, 859

clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics, 141

correlation of antifactor Xa concentrations with renal function in patients on enoxaparin, 586

delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity, 171

dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics, 1216

effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031, 1341

effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy, 52

effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, 260

effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects, 187

effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans, 524

factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies, 1124

furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers, 711

galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations, 514

gastric function in the elderly: effects on absorption of ketoconazole, 996

individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects, 1268

influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide, 649

influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects, 59

influence of goldenseal root on the pharmacokinetics of indinavir, 1283

influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist, 15

influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study, 1235

lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal, 990

lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects, 912

levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets, 1370

a limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients, 894

long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients, 866

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients, 1101

model appropriateness and population pharmacokinetic modeling, 610

pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects, 727

pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-*O*-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects, 1350

pharmacokinetic and safety assessment of concurrent administration of risperidone and donepezil, 180

pharmacokinetic strategies in deciphering atypical drug absorption profiles, 211

pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women, 243

pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients, 1329

pharmacokinetics and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone, 1274

pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects, 74

pharmacokinetics and pharmacodynamics of a single bolus of propofol 2% in healthy volunteers, 397

pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients, 624

pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion, 1324

pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function, 154

pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis, 43

pharmacokinetics interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and four hours apart in healthy volunteers, 1168

pharmacokinetics of O^6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O^6-benzylguanine, 881

pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration, 1149

pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury, 379

pharmacokinetics of cyclosporine pre- and post-liver transplantation, 38

pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function, 1361

pharmacokinetics of etoricoxib in patients with hepatic impairment, 1136

pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients, 1003

pharmacokinetics of nateglinide in renally impaired diabetic patients, 163

pharmacokinetics of oral ibuprofen in premature infants, 968

pharmacokinetics of pregabalin in subjects with various degrees of renal function, 277

pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment, 128

pharmacokinetics of repaglinide in health Caucasian and Japanese subjects, 23

pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency, 252

pharmacokinetics of sumatriptan nasal spray in adolescents, 721

pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment, 591

pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers, 529

plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers, 1257

population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children, 386

population pharmacokinetics and pharmacodynamics of ciclesonide, 365

population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children, 133

population pharmacokinetics of ciprofloxacin in pediatric patients, 698

ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes, 1244

relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation, 983

safety and pharmacokinetics of ReN1869: a first human dose study in healthy subjects after single-dose administration, 66

safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects, 901

safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study, 735

single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man, 268

single- and multiple-dose pharmacokinetics of oral creatine, 29

single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study, 406

tegaserod pharmacokinetics are similar in patients with sever renal insufficiency and in healthy subjects, 359

tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia, 565

tyramine pharmacokinetics and reduced bioavailability with food, 604

use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem, 1116

valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization, 974

young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison, 1228

Phenobarbital

clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios, 491

Phenylephrine

reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin $F_{2\alpha}$ using the dorsal hand vein compliance method, 228

PHICO's event reporting trending system (PERTS)

medication errors: an analysis comparing PHICO's closed claims data and PHICO's event reporting trending system (PERTS), 754

Plasma

pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients, 1003

pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion, 1324

plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers, 1257

Plasma concentration

long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients, 866

Plasma study

influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study, 1235

Plasma tissue

pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects, 727

Platelet aggregation

relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation, 983

Platelet function

COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial, 504

Porphyria

renal transplantation in a case of acute intermittent porphyria, 1158

PPARα

ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes, 1244

Pravastatin

individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects, 1268

Prednisolone

effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects, 187

Prednisone

effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects, 187

Pregabalin

pharmacokinetics of pregabalin in subjects with various degrees of renal function, 277

Propofol

pharmacokinetics and pharmacodynamics of a single bolus of propofol 2% in healthy volunteers, 397

Prostaglandin

reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin $F_{2\alpha}$ using the dorsal hand vein compliance method, 228

Quazepam

interaction study between fluvoxamine and quazepam, 1392

Quinapril

pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment, 128

Ragaglitazar

ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes, 1244

Rapaglinide

pharmacokinetics of repaglinide in health Caucasian and Japanese subjects, 23

ReN1869

safety and pharmacokinetics of ReN1869: a first human dose study in healthy subjects after single-dose administration, 66

Renal function

correlation of antifactor Xa concentrations with renal function in patients on enoxaparin, 586

famotidine disposition in children and adolescents with chronic renal insufficiency, 7

pharmacokinetics of pregabalin in subjects with various degrees of renal function, 277

pharmacokinetics of nateglinide in renally impaired diabetic patients, 163

pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function, 154

pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency, 252

tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects, 359

Renal functions

pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis, 43

Renal impairment

pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment, 591

Renal transplant

effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients, 555

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients, 1101

renal transplantation in a case of acute intermittent porphyria, 1158

Renin

can renin status predict the antihypertensive efficacy of eplerenone add-on therapy, 1203

Repaglinide

influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide, 649

Rifampicin

lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide, 1382

Risperidone

effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia, 122

pharmacokinetic and safety assessment of concurrent administration of risperidone and donepezil, 180

Ritonavir

short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone, 414

Rofecoxib

an evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe, 1082

effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects, 187

Rosiglitazone

pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency, 252

RWJ 67657

single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study, 406

Saliva study

influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study, 1235

Schizophrenia

effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia, 122

Seirogan

multiple-dose escalation, safety, and tolerability study of wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medication in healthy subjects, 284

Serum calcitriol

a limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients, 894

Serum homocysteine

comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia, 825

Simvastatin

comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia, 825

effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers, 428

Single-trough concentrations

considerations in analyzing single-trough concentrations using mixed-effects modeling, 1307

Sirolimus

pharmacokinetics interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and four hours apart in healthy volunteers, 1168

Sodium

influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects, 59

Soy

drug interaction potential of soy extract and panax ginseng, 643

Spinal cord injury

pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury, 379

Steroids

effect of inhaled steroids on bone mineral density: a meta-analysis, 193

Sumatriptan

pharmacokinetics of sumatriptan nasal spray in adolescents, 721

Swelling

ketoprofen 75 mg qid versus acetaminophen 1000 mg qid for three days on swelling, pain, and other postoperative events after third-molar surgery, 305

Tacrolimus

chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection, 859

long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients, 866

Tegaserod

tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects, 359

Theophylline

an evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe, 1082

Thrombin inhibitors

are coagulation times biomarkers? Data from a phase I study of the oral thrombin inhibitor LB-30057 (CI-1028), 118

Tinzaparin

pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects, 727

Tolbutamide

tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans, 84

Topiramate

clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios, 491

Trazodone

short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone, 414

Tyramine

tyramine pharmacokinetics and reduced bioavailability with food, 604

Ulcer

polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of *Helicobacter pylori* infection associated with duodenal ulcer, 1316

United States Pharmacopeia (UPS)

medication errors: experience of the United States Pharmacopeia (UPS) MEDMARX reporting system, 760

Valdecoxib

COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial, 504

valdecoxib, a COX-2-speicific inhibitor, does not affect cardiac repolarization, 974

Vardenafil

effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, 260

Vitamin C

pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E, 1161

Vitamin E

pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E, 1161

VLA-4

effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031, 1341

Wood creosote

multiple-dose escalation, safety, and tolerability study of wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medication in healthy subjects, 284

Xa

correlation of antifactor Xa concentrations with renal function in patients on enoxaparin, 586

Zidovudine

population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children, 133

Zoledronic acid

pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function, 154